NASDAQ: ALDX
Aldeyra Therapeutics Inc Stock Ownership - Who owns Aldeyra Therapeutics?

Insider buying vs selling

Have Aldeyra Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Michael AlfieriPrincipal Financial Officer2025-08-132,500$5.30
$13.25kBuy
Stephen MacHathaChief Development Officer2025-08-1122,073$5.15
$113.72kSell
Perceptive Advisors LLC10% Owner2025-04-033,400,000$1.42
$4.83MSell

1 of 1

ALDX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALDX insiders and whales buy or sell their stock.

ALDX Shareholders

What type of owners hold Aldeyra Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Perceptive Advisors LLC14.07%8,465,302$39.53MInsider
Knoll Capital Management LLC9.10%5,475,516$25.57MInstitution
Perceptive Advisors LLC8.68%5,222,311$24.39MInstitution
Blackrock Inc6.32%3,804,920$17.77MInstitution
Vanguard Group Inc5.97%3,591,869$16.77MInstitution
Domain Partners VI LP3.28%1,973,389$9.22MInsider
Ardsley Advisory Partners LP3.16%1,900,000$8.87MInstitution
Jesse I. Treu3.13%1,885,854$8.81MInsider
Johnson Johnson2.91%1,750,292$8.17MInsider
Aqr Capital Management LLC2.50%1,505,360$7.03MInstitution

1 of 3

ALDX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALDX65.22%27.77%Net Selling
CAMP52.04%47.96%Net Buying
NMRA23.65%76.35%Net BuyingNet Buying
AARD43.48%46.96%Net BuyingNet Buying
ABEO45.75%54.25%Net SellingNet Selling

Aldeyra Therapeutics Stock Ownership FAQ

Who owns Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ: ALDX) is owned by 65.22% institutional shareholders, 27.77% Aldeyra Therapeutics insiders, and 7.01% retail investors. Perceptive Advisors LLC is the largest individual Aldeyra Therapeutics shareholder, owning 8.47M shares representing 14.07% of the company. Perceptive Advisors LLC's Aldeyra Therapeutics shares are currently valued at $39.53M.

If you're new to stock investing, here's how to buy Aldeyra Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.